Europe - FRA:GXI - DE000A0LD6E6 - Common Stock
The current stock price of GXI.DE is 27.4 EUR. In the past month the price decreased by -27.29%. In the past year, price decreased by -64.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TN8.DE | THERMO FISHER SCIENTIFIC INC | 25.24 | 184.80B | ||
| DAP.DE | DANAHER CORP | 28 | 133.74B | ||
| LO3.DE | LONZA GROUP AG-REG | 35.87 | 42.04B | ||
| QTS.DE | IQVIA HOLDINGS INC | 18.61 | 31.86B | ||
| DIM.PA | SARTORIUS STEDIM BIOTECH | 48 | 20.14B | ||
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 48.07 | 20.17B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 52 | 17.75B | ||
| ILU.DE | ILLUMINA INC | 28.05 | 16.25B | ||
| SRT.DE | SARTORIUS AG | 41.58 | 14.20B | ||
| ERF.PA | EUROFINS SCIENTIFIC | 16.99 | 11.14B | ||
| ESF0.DE | EUROFINS SCIENTIFIC | 16.96 | 11.12B | ||
| QIA.DE | QIAGEN N.V. | 19.85 | 8.74B |
Gerresheimer AG engages in the manufacturing and supplies glass and plastic products for the pharmaceutical and healthcare industry. The company is headquartered in Dusseldorf, Nordrhein-Westfalen and currently employs 13,535 full-time employees. The company went IPO on 2007-06-11. The company operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The firm operates approximately 40 production facilities in Europe, North America, South America and Asia.
GERRESHEIMER AG
Klaus-Bungert-Strasse 4
Dusseldorf NORDRHEIN-WESTFALEN DE
Employees: 13535
Phone: 49211618100
Gerresheimer AG engages in the manufacturing and supplies glass and plastic products for the pharmaceutical and healthcare industry. The company is headquartered in Dusseldorf, Nordrhein-Westfalen and currently employs 13,535 full-time employees. The company went IPO on 2007-06-11. The company operates through two business segments: Plastics and Devices, and Primary Packaging Glass. The Plastics and Devices segment produces standard and customized products for drug delivery, such as insulin pens, inhalers, and prefillable syrings. The Primary Packaging Glass segment focuses on the production of packaging of glass for medicines and cosmetics, such as pharmaceuticals jars, ampoules, injection vials, cartridges, perfume flacons and cream jars, as well as glass containers for the food and beverage industry. The firm operates approximately 40 production facilities in Europe, North America, South America and Asia.
The current stock price of GXI.DE is 27.4 EUR. The price decreased by -0.72% in the last trading session.
GERRESHEIMER AG (GXI.DE) has a dividend yield of 0.14%. The yearly dividend amount is currently 1.32.
GXI.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GXI.DE.
The Revenue of GERRESHEIMER AG (GXI.DE) is expected to grow by 17.05% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
GERRESHEIMER AG (GXI.DE) currently has 13535 employees.
ChartMill assigns a fundamental rating of 3 / 10 to GXI.DE. Both the profitability and financial health of GXI.DE have multiple concerns.
Over the last trailing twelve months GXI.DE reported a non-GAAP Earnings per Share(EPS) of 3.69. The EPS decreased by -19.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.04% | ||
| ROA | 0.5% | ||
| ROE | 1.67% | ||
| Debt/Equity | 1.22 |
23 analysts have analysed GXI.DE and the average price target is 40.1 EUR. This implies a price increase of 46.36% is expected in the next year compared to the current price of 27.4.
For the next year, analysts expect an EPS growth of -18.32% and a revenue growth 17.05% for GXI.DE